COLLABORATION AGREEMENT by and between SURFACE ONCOLOGY, INC. and NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.Collaboration Agreement • November 17th, 2017 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • New York
THIS COLLABORATION AGREEMENT (this “Agreement”), entered into as of January 9, 2016 (the “Effective Date”), is entered into by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Surface”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Novartis”). Surface and Novartis are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 17th, 2017 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Agreement is effective as of September 23, 2015 (the “Effective Date”), by and between Harbour Antibodies B.V., a Netherlands corporation located at Erasmus MC Building EE, Room 07-22, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands (“Harbour”), and Surface Oncology, Inc., a Delaware corporation located at 215 First Street, Suite 400-S, Cambridge, MA 02142, USA (“Surface”). Harbour and Surface are each sometimes referred to herein as a “Party” or collectively as the “Parties.”
DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • November 17th, 2017 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS DEVELOPMENT AND OPTION AGREEMENT (the “Agreement”) is made effective as of July 3, 2014 (the “Effective Date”), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (“Surface”).
